Sign In
Buy MBRX
$2.46
+0 (+0%)
At Close: Jun 03, 2026
Moleculin Announces Proposed Underwritten Public Offering
04:22pm, Tuesday, 02'nd Feb 2021
HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin
MBRX Stock Price Increases Over 60% Pre-Market: Why It Happened
09:16am, Tuesday, 02'nd Feb 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) is trading at over 60% pre-market as of 9:12 AM ET. This is why it happened.
Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial
07:30am, Monday, 01'st Feb 2021
HOUSTON, Feb. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
MBRX Stock Price Increases Over 400% Pre-Market: Why It Happened
07:08am, Monday, 01'st Feb 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) has increased by over 400% pre-market. This is why it happened.
Moleculin Announces Reverse Stock Split
09:15am, Friday, 29'th Jan 2021
HOUSTON, Jan. 29, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Biotech (MBRX) Jumps: Stock Rises 8.5%
11:17am, Tuesday, 12'th Jan 2021
Moleculin Biotech (MBRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference
07:30am, Thursday, 07'th Jan 2021
HOUSTON, Jan. 7, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
07:30am, Tuesday, 29'th Dec 2020
HOUSTON, Dec. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
07:30am, Thursday, 17'th Dec 2020
HOUSTON, Dec. 17, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
HOUSTON, Dec. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
MBRX Stock: Why Moleculin Biotech Is Soaring 21% Today
12:47pm, Tuesday, 01'st Dec 2020
Moleculin Biotech (MBRX) is seeing shares of MBRX stock soar higher on Tuesday after announcing news concerning one of its drug candidates. The post MBRX Stock: Why Moleculin Biotech Is Soaring 21% To
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
07:30am, Tuesday, 01'st Dec 2020
HOUSTON, Dec. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML
07:30am, Thursday, 19'th Nov 2020
HOUSTON, Nov. 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020
07:30am, Friday, 13'th Nov 2020
HOUSTON, Nov. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19
07:30am, Thursday, 29'th Oct 2020
HOUSTON, Oct. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
